Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
41 - 50 of 101
- Decentralization of Next-Generation RNA Sequencing-Based MammaPrint (R) and BluePrinti (R) Kit at University Hospitals Leuven and Curie Institute Paris(2019)
Authors: Laurence Slembrouck, Lauren Darrigues, Cecile Laurent, Lorenza Mittempergher, Leonie JMJ Delahaye, Isabelle Vanden Bempt, Sara Vander Borght, Liesbet Vliegen, Petra Sintubin, Virginie Raynal, et al.
Pages: 1557 - 1565 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev(2019)
Authors: Els Van Nieuwenhuysen
- IDENTIFICATION OF P53 PRIONS AS AN INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER(2019)
Authors: Nicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, Stuart Wilson, Georg Heinze, Christine Wallisch, Reinhard Horvat, Jalid Sehouli, Ioana Braicu, Ignace Vergote, et al.
Pages: 76 - 76 - Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)(2019)
Authors: Xia Jiang, Hilary K Finucane, Fredrick R Schumacher, Stephanie L Schmit, Jonathan P Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B Kuchenbaecker, Joe Dennis, et al.
- The association between weight at birth and breast cancer risk revisited using Mendelian randomisation(2019)
Authors: Kevin Punie, Els Van Nieuwenhuysen
Pages: 591 - 600 - Loss of 1p36.33 Frequent in low-Grade Serous Ovarian Cancer(2019)
Authors: Els Van Nieuwenhuysen, Pieter Busschaert, Annouschka Laenen, Sileny Han, Patrick Neven, Diether Lambrechts, Ignace Vergote
Pages: 582 - 590 - Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women(2019)
Authors: Diether Lambrechts, Ignace Vergote, Els Van Nieuwenhuysen
Pages: 2503 - 2513 - Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium(2019)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 1063 - 1073 - Shared heritability and functional enrichment across six solid cancers(2019)
Authors: Frank Claessens, Diether Lambrechts, Els Van Nieuwenhuysen
- Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival(2018)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 1002 - 1012